Dr. David M. Jablons

Chief of Thoracic Surgery

UCSF Medical Center at Mount Zion

Helen Diller Family Comprehensive Cancer Center
1600 Divisadero Street, Fourth Floor
San Francisco, CA 94143
(415) 885-3882

Yale University

Albany Medical College of Union University - 1984

Tufts-New England Medical Center

Cornell University Medical Center

Professional Highlights

Dr. David Jablons is program leader of the Thoracic Oncology Program at the USCF Comprehensive Cancer Center and chief of General Thoracic Surgery at UCSF Medical Center. He is a world renowned expert on lung cancer, and a leader in surgical therapy for thoracic malignancies such as pleural mesothelioma. He directs the UCSF Thoracic Oncology Laboratory, where he focuses on the molecular biology and genomics of lung cancer. He is the author of numerous research papers, and is frequently asked to lecture about lung cancer at meetings around the world.

Educational Background and Professional Appointments

Dr. Jablons earned his medical degree from Albany Medical College of Union University. His surgical residency was completed at Tufts-New England Medical Center and Cardiothoracic fellowship at Cornell University Medical Center. Dr. Jablons is board certified in Surgery and Thoracic Surgery. He is a member of the Society of Thoracic Surgeons, the American Association for the Advancement of Science, the International Association for the Study of Lung Cancer and the American Association for Cancer Research. He was awarded special recognition as the Ada Distinguished Professor of Thoracic Oncology.

Relevant Publications by David M. Jablons, MD

Update on the molecular biology of malignant mesothelioma.
Cancer. 2007 Apr 15;109(8):1454-61. Review.
PMID: 17348013 [PubMed - indexed for MEDLINE]
Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma.
Biochem Biophys Res Commun. 2006 Apr 21;342(4):1228-32. Epub 2006 Feb 24.
PMID: 16516163 [PubMed - indexed for MEDLINE]
Wnt2 as a new therapeutic target in malignant pleural mesothelioma.
Int J Cancer. 2005 Nov 1;117(2):326-32.
PMID: 15900580 [PubMed - indexed for MEDLINE]
Wang ZJ, Reddy GP, Gotway MB, Higgins CB, Jablons DM, Ramaswamy M, Hawkins RA, Webb WR. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. Radiographics, Issue: 1. 24: 105-19, 2004.
You L, He B, Uematsu K, Xu Z, Mazieres J, Lee A, McCormick F, Jablons DM. Inhibition of Wnt-1 signaling induces apoptosis in beta-catenin-deficient mesothelioma cells. Cancer Res, Issue: 10. 64: 3474-8, May/15/2004.
Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, Maki RA, Jablons DM, Husain SR, Puri RK. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts. Ann Thorac Surg, Issue: 2. 78: 436-43; discussion 436-43, Aug/2004.
Lee AY, He B, You L, Dadfarmay S, Xu Z, Mazieres J, Mikami I, McCormick F, Jablons DM. Expression of the secreted frizzled-related protein gene family is downregulated in human mesothelioma. Oncogene, Issue: 39. 23: 6672-6, Aug/26/2004.
Lee AY, He B, You L, Xu Z, Mazieres J, Reguart N, Mikami I, Batra S, Jablons DM. Dickkopf-1 antagonizes Wnt signaling independent of beta-catenin in human mesothelioma. Biochem Biophys Res Commun, Issue: 4. 323: 1246-50, Oct/29/2004.
He B, Lee AY, Dadfarmay S, You L, Xu Z, Reguart N, Mazieres J, Mikami I, McCormick F, Jablons DM. Secreted frizzled-related protein 4 is silenced by hypermethylation and induces apoptosis in beta-catenin-deficient human mesothelioma cells. Cancer Res, Issue: 3. 65: 743-8, Feb/1/2005.
Dresler CM, Olak J, Herndon JE, Richards WG, Scalzetti E, Fleishman SB, Kernstine KH, Demmy T, Jablons DM, Kohman L, Daniel TM, Haasler GB, Sugarbaker DJ, , , ,. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest, Issue: 3. 127: 909-15, Mar/2005.
Mazieres J, You L, He B, Xu Z, Twogood S, Lee AY, Reguart N, Batra S, Mikami I, Jablons DM. Wnt2 as a new therapeutic target in malignant pleural mesothelioma. Int J Cancer, Issue: 2. 117: 326-32, Nov/1/2005.
Kim KU, Wilson SM, Abayasiriwardana KS, Collins R, Fjellbirkeland L, Xu Z, Jablons DM, Nishimura SL, Broaddus VC. A novel in vitro model of human mesothelioma for studying tumor biology and apoptotic resistance. Am J Respir Cell Mol Biol, Issue: 6. 33: 541-8, Dec/2005.
Batra S, Shi Y, Kuchenbecker KM, He B, Reguart N, Mikami I, You L, Xu Z, Lin YC, Clément G, Jablons DM. Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. Biochem Biophys Res Commun, Issue: 4. 342: 1228-32, Apr/21/2006.